Zevra Therapeutics (ZVRA) Cash & Current Investments (2014 - 2026)

Zevra Therapeutics has reported Cash & Current Investments for 13 years, with the latest figure at $200.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 220.31% year-over-year to $200.6 million; the trailing twelve-month figure through Mar 2026 stood at $200.6 million (up 220.31% YoY), and the FY2025 full-year result was $191.0 million, up 174.85% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $200.6 million, up from $191.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $202.6 million in Q2 2025, with the low at $40.2 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $101.6 million across 5 years, with a median of $70.1 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 46.72% — and 2025, when it jumped 311.33%.
• Zevra Therapeutics' Cash & Current Investments stood at $82.4 million in 2022, then slipped by 17.76% to $67.7 million in 2023, then increased by 2.6% to $69.5 million in 2024, then surged by 174.85% to $191.0 million in 2025, then advanced by 5.03% to $200.6 million in 2026.
• The last three Cash & Current Investments figures came in at $200.6 million (Q1 2026), $191.0 million (Q4 2025), and $199.5 million (Q3 2025), per Business Quant data.